News & Updates
Filter by Specialty:
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
A post-hoc analysis of a phase III trial of long-term safinamide for Parkinson’s disease (PD) finds a significant early increase in pre-existing dyskinesia as well as improved motor symptoms in patients with or without pre-existing dyskinesia at 1 year.
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
12 Oct 2022
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
10 Oct 2022
Early sleep, longer time in bed tied to dementia risk in older adults
Older adults who sleep before 9 P.M. and have prolonged sleep duration appear to be at an increased risk of dementia, a recent study has found.
Early sleep, longer time in bed tied to dementia risk in older adults
07 Oct 2022
AF increases susceptibility to stroke associated with air pollution exposure
Atrial fibrillation (AF) exacerbates the effect of air pollution exposure on acute ischaemic stroke outcomes, such that AF patients are more likely to develop stroke when exposed to increasing levels of smog (O3) and carbon monoxide (CO) compared with those who have no AF, according to a Singapore study.